Authors
Latest:
Dr. Lesser on Armodafinil for Radiation-Induced FatigueGlenn J. Lesser, MD, Professor, Hematology & Oncology, Comprehensive Cancer Center, Wake Forest Baptist Health, discusses armodafinil for brain radiation-induced fatigue.
Latest:
The Prostate Cancer Paradox RevisitedConflicting guidelines on prostate-specific antigen testing have affected trends on disease presentation and, potentially, the treatment outcomes for many men with this disease. New agents and powerful new imaging tools have added yet more complexity to the decision process. Therefore, more investigation and cooperation on multiple levels is needed to define appropriate standards of care.
Latest:
Dr. Sapisochin on the Benefits of Living Donor Transplant in HCCGonzalo Sapisochin, MD, discusses the benefits of living donor liver transplantation in hepatocellular carcinoma.
Latest:
Dr. Iyer on Unmet Needs for Patients With TSC1/2-mutated Solid TumorsGopa Iyer, MD, discusses the unmet needs for patients with solid tumors harboring TSC1/2 mutations.
Latest:
Dr. Mills Gives Examples of Unexpected Drug ResponsesDr. Gordon Mills from MD Anderson Cancer Center Gives Examples of Unexpected Therapy Responses
Latest:
Advances in Metastatic Melanoma Bring Price Competition, Redefinition of Value, and Likely Increased Payer Utilization ManagementTraditionally, payers have been increasingly more proactive in their management of drug expenditures in cancers with the highest prevalence and with the more costly therapeutics.
Latest:
Dr Konecny on PROs From the MIRASOL Trial in Advanced Ovarian CancerGottfried Konecny, MD, discusses the importance of evaluating PROs in patients with platinum-resistant ovarian cancer receiving mirvetuximab soravtansine.
Latest:
Recent Advances in MelanomaGrace Cherry, RN, MSN, NP, discusses recent advances in melanoma.
Latest:
Doxorubicin-Loaded Nanoparticle Formulation in Patients With HCCGraham Dixon, PhD, chief scientific officer, Onxeo, discusses a mechanistic study of the relative cytotoxicity of doxorubicin-loaded nanoparticle formulation versus doxorubicin in hepatocellular carcinoma cell lines.
Latest:
Dr. Jackson on Ongoing Challenges in Treating Patients With Multiple MyelomaGraham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses some of the ongoing challenges in the treatment of patients with multiple myeloma.
Latest:
Graham Mann on Genetic Mutations in Different Types of MelanomaGraham Mann, MBBS, PhD, FRACP, professor of Medicine, Westmead Clinical School and co-director of the Centre for Cancer Research, The Westmead Institute for Medical Research at the University of Sydney in Australia, discusses his findings from the Australian Melanoma Genome Project, which were presented at the 2016 Society for Melanoma Research (SMR) Congress.
Latest:
Helping Cancer Patients Quit Smoking Should Be a Standard of CareMost oncologists do not regularly provide evidence-based tobacco cessation support for patients with cancer who smoke. However, addressing tobacco use is not as difficult as some might think.
Latest:
Dr. McArthur Discusses Subpopulation Data from coBRIM Trial in Advanced MelanomaGrant McArthur, PhD, discusses significant results from the final analysis of the coBRIM trial, which evaluated the 5-year survival data of cobimetinib plus vemurafenib in patients with BRAF V600-mutated advanced melanoma.
Latest:
Dr. Carlson on Treating Breast Cancer Patients Under 40Grant W. Carlson, MD, professor of surgery, Emory University School of Medicine, chief, Division of Plastic Surgery, Emory University Hospital, discusses treating younger patients with breast cancer.
Latest:
Individualized Treatment Needed for Patients With NRAS-Mutated mCRCActivating, hotspot mutations in the NRAS gene occur in a small subset of patients with metastatic colorectal cancer. These mutations are now being identified in routine clinical practice by extended RAS genotyping.
Latest:
Dr. Daniels on Immunotherapy in Head and Neck CancerGregory A. Daniels, MD, PhD, medical oncologist, associate professor of medicine, UC San Diego Health, discusses the role of immunotherapy for patients with head and neck cancer.
Latest:
Dr. Grabowski Explains the Effects of Enzyme TherapyDr. Gregory A. Grabowski from Cincinnati Children's Hospital Medical Center Explains the Effects of Enzyme Therapy
Latest:
Dr. Otterson on the Utility of Immunotherapy in NSCLCGregory A. Otterson, MD, discusses data examining immunotherapy alone versus in combination in non–small cell lung cancer.
Latest:
Dr. Idos on Remaining Questions With Multiplex Panel TestingGregory E. Idos, MD, assistant professor of Clinical Medicine, Department of Surgery, Division of Colorectal Surgery, Keck School of Medicine of University of Southern California, sheds light on the remaining questions with multiplex panel testing as well as the cost effectiveness of it.
Latest:
Dr. Beatty on the Potential for Immunotherapy in GI MalignanciesGregory L. Beatty, MD, PhD, assistant professor of medicine, director of Tanslation Research, Pancreatic Cancer Research Center, University of Pennsylvania Perelman School of Medicine, discusses the potential for immunotherapy in gastrointestinal malignancies.
Latest:
Immunotherapy Combined With Chemotherapy for Pancreatic Cancer: A Game Changer?This article reviews up-to-date clinical studies combining chemotherapy with immunotherapy; it also explains the rationale for this combination in treatment of pancreatic cancer.
Latest:
Experts Discuss How to Address Cardiac-Related Toxicities With EGFR TKIsGregory Riely, MD, and Shirish Gadgeel, MD, discuss how to address cardiac-related toxicities associated with treatment with EGFR TKIs.
Latest:
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue SarcomasNeoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.
Latest:
Looking Towards The Future of HR+/HER2- Breast CancerThe expert panel discusses ongoing research and offers closing thoughts on the future of HR+/HER2- breast cancer treatment.
Latest:
Dr. Randolph on Future Treatment Approaches in Thyroid CancerGregory W. Randolph, MD, director, General and Thyroid Surgical Services, Massachusetts General Hospital, discusses the future methods of treating patients with thyroid cancer.
